GLP-1 Use Linked to Improved Survival and Fewer Complications in patients with Diabetes and Cancer: Study
Researchers have found in a new study that adults with type 2 diabetes and cancer who used GLP-1 receptor agonists had a lower risk of death compared with those using metformin. GLP-1 use was also associated with reduced risks of hospitalization, pneumonia, cardiovascular events, and sepsis, according to findings published in The Journal of Clinical Endocrinology & Metabolism.
GLP- 1 RA have been reported to decrease cancer incidence, but less is known about their potential in patients with active cancer. Preclinical studies have demonstrated that GLP-1 RA inhibit progression of solid tumor malignancies via downregulation of cellular proliferation pathways and improved glycemic control. Despite these promising findings, studies characterizing the effects of GLP-1 RA in patients with active cancer are limited.
Patients with diabetes and cancer who received GLP-1 RA experienced superior survival outcomes and reduced rates of hospitalization compared to patients receiving metformin. Additionally, patients already on metformin and newly started on GLP-1 RA demonstrated superior survival outcomes compared to patients newly started on insulin. Further prospective, well-controlled studies are needed to evaluate the benefits of GLP-1 RA in patients with diabetes and cancer.
Reference:
Aditya Mahadevan, Aidan Vosooghi, Jagmeet S Arora, Ruthvik Sunil Kumar, Gagandeep Singh, Katy K Tsai, Zoe Quandt, GLP- 1 Receptor Agonists in Patients with Cancer are Associated with Reduced All-Cause Mortality and Hospitalization, The Journal of Clinical Endocrinology & Metabolism, 2026;, dgaf703, https://doi.org/10.1210/clinem/dgaf703
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.